Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-70218902 |
Synonyms | |
Therapy Description |
JNJ-70218902 is a bispecific antibody targeting TMEFF2-expressing tumor cells and CD3-expressing T-cells, potentially resulting in T-cell-mediated cell death and antitumor activity (NCI Thesaurus, Ann Oncol (2022) 33 (suppl_7): S616-S652). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-70218902 | JNJ70218902|JNJ 70218902|JNJ-902|JNJ 902|JNJ902 | CD3 Antibody 99 | JNJ-70218902 is a bispecific antibody targeting TMEFF2-expressing tumor cells and CD3-expressing T-cells, potentially resulting in T-cell-mediated cell death and antitumor activity (NCI Thesaurus, Ann Oncol (2022) 33 (suppl_7): S616-S652). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04397276 | Phase I | JNJ-70218902 | A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors | Active, not recruiting | ISR | ESP | CAN | 0 |